European Commission/ EUR-Lex: Council Recommendation on Raising seasonal vaccination coverage among risk groups and healthcare workers (22 December 2009)
Council Recommendation on Raising seasonal vaccination coverage among risk groups and healthcare workers (22 December 2009)
Technical report In Brief: Narcolepsy in association with pandemic influenza vaccination
This report summarises the results from two epidemiological studies to investigate a possible association between an unexpected increase in narcolepsy cases following the use of the influenza A(H1N1)pdm09 vaccines. The studies were conducted by the Vaccine Adverse Event Surveillance and Communication (VAESCO) Consortium under the auspices of ECDC and undertaken in Denmark, Finland, France, Italy, the Netherlands, Norway, Sweden and the United Kingdom. This Technical Report In Brief accompanies the full Report ‘Narcolepsy in association with pandemic influenza vaccination- A multi-country European epidemiological investigation’.
Communicable disease threats report, 16-22 April 2017, week 16
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 16-22 April 2017 and includes updates on influenza, cholera, poliomyelitis, measles, legionnaires' disease and yellow fever.
- Avian influenza virus
- Food- and Waterborne Diseases and Zoonoses Programme
- Influenza and other Respiratory Viruses Programme
- Influenza in humans, seasonal
- Legionnaires’ disease
- Public health threat
- South America
- Vaccine Preventable Diseases Programme
- Yellow fever
Risk assessment: Seasonal influenza 2012/13 in Europe (EU/EEA countries)
ECDC has produced an annual risk assessment of the seasonal influenza epidemics in Europe since the 2010/11 season following the model developed by ECDC during the 2009 pandemic. It gives an early description of the influenza season in the countries affected earliest, providing guidance and information to countries that are affected later, as influenza progresses across Europe over several months. It describes any specifics of the season, particularly in areas where public health or clinical actions are envisaged, as well as highlights areas of uncertainty where further work is required.
Communicable disease threats report, 30 July - 5 August, week 31
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 30 July – 5 August 2017 and includes updates on hepatitis A, West Nile virus, Vibrio, measles, seasonal influenza, MERS, and Legionnaires' disease.
Communicable disease threats report, 6–12 August 2017, week 32
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 6–12 August 2017 and includes updates on poliomyelitis, cholera, measles, Legionnaires' disease, West Nile virus, seasonal influenza, and malaria.
Communicable disease threats report, 13-19 August 2017, week 33
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 13-19 August 2017 and includes updates on measles, West Nile fever, Chikungunya and influenza.
Influenza virus characterisation, Summary Europe, June 2017
In the course of the 2016–2017 influenza season, nearly 146 000 influenza detections across the EU/EAA region have been reported.
Influenza virus characterisation, Summary Europe, July 2017
In the course of the 2016–17 influenza season, nearly 146 000 influenza detections have been reported across the WHO European Region.
Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States. Recommendations to treat patients with severe influenza – or those at high risk of the complications of influenza – and provide prophylaxis to the most vulnerable and their families are based on the evidence from randomised controlled trials, evidence from observational studies, extrapolation from studies, and a generally benign safety profile of these medicines.